Your browser doesn't support javascript.
Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors.
Tan, Chee-Wah; Chia, Wan-Ni; Young, Barnaby E; Zhu, Feng; Lim, Beng-Lee; Sia, Wan-Rong; Thein, Tun-Linn; Chen, Mark I-C; Leo, Yee-Sin; Lye, David C; Wang, Lin-Fa.
  • Tan CW; From the Programme in Emerging Infectious Diseases, Duke-NUS (National University of Singapore) Medical School (C.-W.T., W.-N.C., F.Z., B.-L.L., W.-R.S., L.-F.W.), the National Centre for Infectious Diseases (B.E.Y., T.-L.T., M.I.-C.C., Y.-S.L., D.C.L.), Tan Tock Seng Hospital (B.E.Y., M.I.-C.C., Y.
  • Chia WN; From the Programme in Emerging Infectious Diseases, Duke-NUS (National University of Singapore) Medical School (C.-W.T., W.-N.C., F.Z., B.-L.L., W.-R.S., L.-F.W.), the National Centre for Infectious Diseases (B.E.Y., T.-L.T., M.I.-C.C., Y.-S.L., D.C.L.), Tan Tock Seng Hospital (B.E.Y., M.I.-C.C., Y.
  • Young BE; From the Programme in Emerging Infectious Diseases, Duke-NUS (National University of Singapore) Medical School (C.-W.T., W.-N.C., F.Z., B.-L.L., W.-R.S., L.-F.W.), the National Centre for Infectious Diseases (B.E.Y., T.-L.T., M.I.-C.C., Y.-S.L., D.C.L.), Tan Tock Seng Hospital (B.E.Y., M.I.-C.C., Y.
  • Zhu F; From the Programme in Emerging Infectious Diseases, Duke-NUS (National University of Singapore) Medical School (C.-W.T., W.-N.C., F.Z., B.-L.L., W.-R.S., L.-F.W.), the National Centre for Infectious Diseases (B.E.Y., T.-L.T., M.I.-C.C., Y.-S.L., D.C.L.), Tan Tock Seng Hospital (B.E.Y., M.I.-C.C., Y.
  • Lim BL; From the Programme in Emerging Infectious Diseases, Duke-NUS (National University of Singapore) Medical School (C.-W.T., W.-N.C., F.Z., B.-L.L., W.-R.S., L.-F.W.), the National Centre for Infectious Diseases (B.E.Y., T.-L.T., M.I.-C.C., Y.-S.L., D.C.L.), Tan Tock Seng Hospital (B.E.Y., M.I.-C.C., Y.
  • Sia WR; From the Programme in Emerging Infectious Diseases, Duke-NUS (National University of Singapore) Medical School (C.-W.T., W.-N.C., F.Z., B.-L.L., W.-R.S., L.-F.W.), the National Centre for Infectious Diseases (B.E.Y., T.-L.T., M.I.-C.C., Y.-S.L., D.C.L.), Tan Tock Seng Hospital (B.E.Y., M.I.-C.C., Y.
  • Thein TL; From the Programme in Emerging Infectious Diseases, Duke-NUS (National University of Singapore) Medical School (C.-W.T., W.-N.C., F.Z., B.-L.L., W.-R.S., L.-F.W.), the National Centre for Infectious Diseases (B.E.Y., T.-L.T., M.I.-C.C., Y.-S.L., D.C.L.), Tan Tock Seng Hospital (B.E.Y., M.I.-C.C., Y.
  • Chen MI; From the Programme in Emerging Infectious Diseases, Duke-NUS (National University of Singapore) Medical School (C.-W.T., W.-N.C., F.Z., B.-L.L., W.-R.S., L.-F.W.), the National Centre for Infectious Diseases (B.E.Y., T.-L.T., M.I.-C.C., Y.-S.L., D.C.L.), Tan Tock Seng Hospital (B.E.Y., M.I.-C.C., Y.
  • Leo YS; From the Programme in Emerging Infectious Diseases, Duke-NUS (National University of Singapore) Medical School (C.-W.T., W.-N.C., F.Z., B.-L.L., W.-R.S., L.-F.W.), the National Centre for Infectious Diseases (B.E.Y., T.-L.T., M.I.-C.C., Y.-S.L., D.C.L.), Tan Tock Seng Hospital (B.E.Y., M.I.-C.C., Y.
  • Lye DC; From the Programme in Emerging Infectious Diseases, Duke-NUS (National University of Singapore) Medical School (C.-W.T., W.-N.C., F.Z., B.-L.L., W.-R.S., L.-F.W.), the National Centre for Infectious Diseases (B.E.Y., T.-L.T., M.I.-C.C., Y.-S.L., D.C.L.), Tan Tock Seng Hospital (B.E.Y., M.I.-C.C., Y.
  • Wang LF; From the Programme in Emerging Infectious Diseases, Duke-NUS (National University of Singapore) Medical School (C.-W.T., W.-N.C., F.Z., B.-L.L., W.-R.S., L.-F.W.), the National Centre for Infectious Diseases (B.E.Y., T.-L.T., M.I.-C.C., Y.-S.L., D.C.L.), Tan Tock Seng Hospital (B.E.Y., M.I.-C.C., Y.
N Engl J Med ; 385(15): 1401-1406, 2021 10 07.
Artigo em Inglês | MEDLINE | ID: covidwho-1361670
ABSTRACT
Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern pose a challenge to the effectiveness of current vaccines. A vaccine that could prevent infection caused by known and future variants of concern as well as infection with pre-emergent sarbecoviruses (i.e., those with potential to cause disease in humans in the future) would be ideal. Here we provide data showing that potent cross-clade pan-sarbecovirus neutralizing antibodies are induced in survivors of severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) infection who have been immunized with the BNT162b2 messenger RNA (mRNA) vaccine. The antibodies are high-level and broad-spectrum, capable of neutralizing not only known variants of concern but also sarbecoviruses that have been identified in bats and pangolins and that have the potential to cause human infection. These findings show the feasibility of a pan-sarbecovirus vaccine strategy. (Funded by the Singapore National Research Foundation and National Medical Research Council.).
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: Síndrome Respiratória Aguda Grave / Coronavírus Relacionado à Síndrome Respiratória Aguda Grave / Anticorpos Amplamente Neutralizantes / Vacinas contra COVID-19 / SARS-CoV-2 / COVID-19 / Anticorpos Antivirais Tipo de estudo: Estudo prognóstico / Ensaios controlados aleatorizados Tópicos: Vacinas / Variantes Limite: Humanos Idioma: Inglês Revista: N Engl J Med Ano de publicação: 2021 Tipo de documento: Artigo

Similares

MEDLINE
LILACS
LIS
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Assunto principal: Síndrome Respiratória Aguda Grave / Coronavírus Relacionado à Síndrome Respiratória Aguda Grave / Anticorpos Amplamente Neutralizantes / Vacinas contra COVID-19 / SARS-CoV-2 / COVID-19 / Anticorpos Antivirais Tipo de estudo: Estudo prognóstico / Ensaios controlados aleatorizados Tópicos: Vacinas / Variantes Limite: Humanos Idioma: Inglês Revista: N Engl J Med Ano de publicação: 2021 Tipo de documento: Artigo